Moya Moya Disease

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Clinicians must exercise independent medical judgment in all aspects of patient care. Always refer to the latest guidelines and consult with specialists as appropriate.

Overview

• Definition: Moya Moya disease (MMD) is a rare, progressive cerebrovascular disorder characterized by the idiopathic, bilateral, chronic, and progressive stenosis or occlusion of the supraclinoid internal carotid arteries (ICAs) and their proximal branches (anterior cerebral artery [ACA] and middle cerebral artery [MCA]). This narrowing leads to the compensatory development of an abnormal collateral vascular network at the base of the brain, giving a "puff of smoke" appearance on angiography (Japanese: "Moya Moya"). This term encompasses both idiopathic Moya Moya disease and Moya Moya syndrome, which is associated with underlying conditions.

• Epidemiology:

  • Prevalence: Very rare. Exact prevalence is unknown, but incidence is estimated to be 0.53 to 2.9 per 100,000 person-years in East Asia, significantly lower in Western countries (0.086 per 100,000 for all ages).
  • Age: Bimodal age distribution. The first peak occurs in childhood (typically 5-10 years) and the second peak in adulthood (30-50 years).
  • Sex: Female predominance, with a female-to-male ratio of approximately 1.8:1 to 2.5:1.
  • Geography: Considerably more common in East Asian populations (Japan, Korea, China) than in Caucasian populations, suggesting genetic predisposition.
  • Familial Form: While most cases are sporadic, approximately 10-15% of cases are familial, with autosomal dominant inheritance with incomplete penetrance suspected.

• Classification:

  • Moya Moya Disease (Idiopathic): Primary form with no identifiable underlying cause, typically bilateral, progressive.
  • Moya Moya Syndrome (Associated Moya Moya): Moya Moya angiographic findings secondary to an underlying systemic or genetic condition. This distinction is crucial for management and prognosis. Associated conditions include:
    • Genetic Syndromes: Down syndrome, Neurofibromatosis type 1 (NF1), Sickle cell disease, Tuberous sclerosis, Alagille syndrome, Marfan syndrome, Ehlers-Danlos syndrome.
    • Inflammatory/Autoimmune Diseases: Graves' disease, Systemic lupus erythematosus (SLE), Crohn's disease, Sarcoidosis.
    • Infections: Meningitis (e.g., tuberculous), Varicella-zoster virus.
    • Radiation Therapy: Cranial irradiation (e.g., for brain tumors, leukemia) is a significant cause of Moya Moya syndrome, often presenting unilaterally initially but can progress bilaterally.
    • Atherosclerosis: Rarely, severe atherosclerosis at the carotid bifurcation can mimic Moya Moya.
    • Connective Tissue Disorders: Such as pseudoxanthoma elasticum.

Pathophysiology

• Mechanism:

  • Stenosis/Occlusion: The hallmark is progressive, non-atherosclerotic, non-inflammatory narrowing or occlusion of the terminal portion of the internal carotid arteries and the proximal segments of the anterior and middle cerebral arteries. Histopathologically, this involves intimal thickening and stenosis with wavy internal elastic lamina, but without significant atherosclerosis or inflammatory infiltrates.
  • Collateral Formation: As cerebral blood flow (CBF) decreases due to proximal stenosis, the brain attempts to compensate by developing an intricate network of fragile, dilated collateral vessels (lenticulostriate, thalamoperforating, and choroidal arteries) from the basal ganglia, thalamus, and perforating arteries. These are the characteristic "Moya Moya" vessels. Pial-pial anastomoses and external carotid artery-to-internal carotid artery anastomoses (e.g., via middle meningeal artery) can also develop.
  • Ischemic Episodes: The fragile Moya Moya vessels are prone to rupture (hemorrhage) due to increased hemodynamic stress, and are also insufficient to meet metabolic demands, especially during periods of increased demand (e.g., crying, exercise, fever, hyperventilation), leading to transient ischemic attacks (TIAs) or strokes.
  • Hemorrhagic Episodes: These frequently occur in adults (more so than children) due to rupture of the fragile Moya Moya collaterals or associated aneurysms. The thin-walled Moya Moya vessels lack the normal arterial wall structure and are under high pressure.

• Risk Factors:

  • Genetic Predisposition: East Asian ethnicity, familial history of MMD. Specific genes are implicated, including RNF213 (especially in East Asian populations).
  • Underlying Conditions: Presence of any condition associated with Moya Moya syndrome (e.g., Down syndrome, NF1, Sickle cell disease, previous cranial radiation).
  • Environmental Factors: Although not well-established, some theories suggest possible associations with certain infections or environmental toxins, though these are largely speculative.

• Protective Factors: None explicitly identified. Early diagnosis and timely revascularization surgery are protective against stroke recurrence and progression of neurological deficits.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:

  • Ischemic Events: Transient ischemic attacks (TIAs) or ischemic strokes are the most common presentations, especially in children. Symptoms are often triggered by hyperventilation, crying, fever, or exercise, which induce vasoconstriction and reduce cerebral blood flow.
  • Hemorrhagic Events: Intracerebral hemorrhage (ICH) is more common in adults than children and can be catastrophic. Subarachnoid hemorrhage (SAH) can also occur.
  • Headache: Chronic headaches, often reported by both children and adults.
  • Seizures: Can occur as a presenting symptom or a complication of stroke.
  • Cognitive Decline: Progressive decline in cognitive function, particularly in children with recurrent ischemic events.

• Early Signs:

  • Children:
    • TIAs: Often present as recurrent episodes of transient hemiparesis, monoparesis, aphasia, visual disturbances (e.g., amaurosis fugax), or numbness, often triggered by crying, blowing a musical instrument, exercise, or fever ("fainting spells").
    • Ischemic Stroke: Acute onset of neurological deficits.
    • Developmental Delay: Subtly impaired cognitive development or fine motor skills.
  • Adults:
    • Hemiparesis/Numbness: Less frequently transient than in children, more often presenting as completed stroke.
    • Headache: Often severe, migraine-like, or atypical.
    • Hemorrhage: Sudden severe headache, altered consciousness, focal neurological deficits.

• Advanced Signs:

  • Progressive Neurological Deficits: Fixed hemiparesis, sensory loss, aphasia, visual field defects.
  • Vascular Dementia: Severe cognitive impairment due to cumulative ischemic injury.
  • Recurrent Hemorrhage: Leading to further neurological decline.

• Atypical Presentations:

  • Pure chorea or dystonia: Due to ischemia in the basal ganglia.
  • Psychiatric symptoms: Mood changes, behavioral disturbances.
  • Isolated headaches: With no apparent neurological deficits initially.
  • Unilateral presentation: Early in the disease course, especially in Moya Moya syndrome (e.g., radiation-induced).

Physical Examination

• Inspection:

  • Focal neurological deficits: Hemiparesis, facial asymmetry, atrophy (e.g., from prior stroke).
  • Gait abnormalities: Ataxic or spastic gait.
  • Signs of underlying syndromes: Stigmata of NF1 (café-au-lait spots, neurofibromas), Down syndrome (facial features, hypotonia), etc.

• Palpation: Not typically diagnostic for MMD itself, but may reveal signs of underlying conditions (e.g., thyroid goiter in Graves' disease).

• Special Tests:

  • Neuropsychological assessment: To evaluate cognitive function, particularly in children and adults with suspected cognitive decline.
  • Ophthalmologic exam: May reveal retinal ischemia in severe cases, or optic atrophy secondary to prolonged ischemia.

Diagnostic Approach

History Taking

• Key Questions:

  • Onset and nature of symptoms: Acute vs. gradual, transient vs. fixed, frequency, triggers (e.g., crying, exercise, fever, hyperventilation).
  • Previous neurological events: TIAs, strokes, seizures, headaches.
  • Developmental milestones (in children): Any delays or regressions.
  • Family history: Stroke, MMD, genetic disorders.
  • Past medical history: Especially conditions associated with Moya Moya syndrome (e.g., thyroid disease, autoimmune disorders, sickle cell disease, NF1, cranial radiation history).
  • Medications: Current and past.
  • Social history: Tobacco use (a general stroke risk factor, though not specifically linked to MMD etiology).

• Red Flags:

  • Recurrent TIAs or strokes in a young patient without traditional risk factors.
  • Acute onset of severe headache with focal neurological deficits (suggestive of hemorrhage).
  • Progressive decline in cognitive or motor function in a child.
  • Neurological symptoms triggered by hyperventilation or physical exertion.

Laboratory Tests

• First-Line:

  • Complete Blood Count (CBC): To rule out anemia, polycythemia, or underlying hematologic disorders (e.g., sickle cell trait/disease).
  • Basic Metabolic Panel (BMP): Electrolytes, renal function.
  • Thyroid Function Tests (TFTs): To screen for Graves' disease.
  • Autoimmune markers: Antinuclear antibody (ANA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) if an autoimmune etiology is suspected.
  • Genetic testing: Consider for specific associated syndromes (e.g., NF1, Down syndrome) or if familial MMD is suspected (e.g., RNF213 in East Asian populations).

• Confirmatory: No specific blood test confirms MMD. Diagnosis relies primarily on imaging.

• Monitoring:

  • Periodic CBC, TFTs, inflammatory markers: If Moya Moya syndrome is being managed.
  • Lipid panel, glucose: Monitoring general cardiovascular risk factors.

Imaging

• Recommended:

  • Magnetic Resonance Angiography (MRA) and Magnetic Resonance Imaging (MRI) of the Brain:
    • MRA: The primary non-invasive diagnostic tool to visualize the stenosis/occlusion of the supraclinoid ICAs and proximal ACAs/MCAs, and the characteristic Moya Moya collateral vessels, particularly in the basal ganglia, thalami, and leptomeningeal spaces. Flow voids may be seen.
    • MRI (T2-weighted, FLAIR): Can show evidence of prior ischemic strokes, intraparenchymal hemorrhages, signs of chronic ischemia (e.g., white matter hyperintensities), or cerebral atrophy. DWI/PWI sequences can detect acute ischemia and assess perfusion.
  • Digital Subtraction Angiography (DSA):
    • Gold standard for definitive diagnosis and detailed visualization of the cerebrovascular pathology. It provides high-resolution imaging of the stenosis/occlusion, extent of the Moya Moya collateral network, and pial collaterals. Often performed prior to surgery to map the vascular anatomy.
    • Demonstrates narrowing or occlusion of bilateral supraclinoid internal carotid arteries, with associated abnormal collateral networks (Moya Moya vessels) supplying blood to the brain.

• Advanced:

  • CT Angiography (CTA): Can be used as an alternative to MRA, especially in acute settings or when MRI is contraindicated. Can visualize vessel stenosis and some collateralization, though less detailed than DSA or MRA for fine collateral vessels.
  • Transcranial Doppler (TCD): Non-invasive, provides information on blood flow velocities in intracranial arteries. Can detect increased flow velocities in the distal ICA and proximal MCA/ACA, and may show evidence of Moya Moya collaterals. Useful for screening, follow-up, and assessment of hemodynamic compromise.
  • Perfusion Imaging (CTP, MR Perfusion): To assess cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) to identify areas of chronic hypoperfusion and regions at risk for ischemia (e.g., "misery perfusion"). Acetazolamide challenge can be used to evaluate cerebrovascular reserve.
  • Single-Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET): Also used to assess cerebral perfusion and cerebrovascular reserve, particularly with acetazolamide challenge to identify regions with impaired autoregulation and increased risk of future ischemic events.

Management

Acute Management

• Immediate:

  • Stabilize vital signs: Ensure adequate airway, breathing, circulation.
  • Manage blood pressure: Maintain adequate cerebral perfusion in ischemic stroke (avoid hypotension). For hemorrhagic stroke, control severe hypertension to prevent re-bleeding using agents like intravenous nicardipine or labetalol.
  • Address seizures: Administer antiepileptic drugs if seizures occur.
  • Correct underlying triggers: For ischemic attacks triggered by hyperventilation, educate patients (especially children) to avoid triggers and ensure adequate hydration.

• Stabilization:

  • Ischemic stroke:
    • Aspirin: If hemorrhage is excluded, consider antiplatelet therapy (e.g., aspirin 50-325 mg daily) to prevent thrombotic propagation, though evidence is limited specifically for MMD.
    • Fluid management: Maintain normovolemia and euvolemia to optimize cerebral perfusion. Avoid dehydration.
    • Oxygenation: Supplemental oxygen to maintain SpO2 >94%.
  • Hemorrhagic stroke:
    • Neurosurgical consultation: Crucial for potential surgical intervention (e.g., hematoma evacuation, aneurysm clipping/coiling if an associated aneurysm is identified).
    • Intracranial pressure (ICP) monitoring and management: If indicated.

• Emergency:

  • Intravenous thrombolysis (IV tPA): Generally contraindicated in MMD due to the high risk of hemorrhage from the fragile Moya Moya vessels and the thrombotic origin of stroke may be less common than hemodynamic compromise.
  • Mechanical thrombectomy: Typically not indicated for MMD, as the underlying pathology is stenosis, not usually a large vessel occlusion amenable to thrombectomy.

Chronic Management

• Pharmacological:

  • Antiplatelet agents: Low-dose aspirin (e.g., 81 mg daily for children, 81-325 mg daily for adults) is often used to reduce the risk of ischemic events, especially when revascularization is delayed or declined, although strong evidence from randomized controlled trials is lacking specifically for MMD. Clopidogrel may be considered if aspirin is not tolerated.
  • Calcium channel blockers (e.g., Nimodipine): Sometimes used off-label, especially in adults, for cerebral vasospasm or headaches, though not a primary treatment for MMD progression.
  • ACE inhibitors/Angiotensin Receptor Blockers: For blood pressure control, if hypertension is present, aiming for normotension.
  • Statins: For patients with dyslipidemia or other atherosclerotic risk factors, although atherosclerosis is not the primary cause of MMD.
  • Antiepileptics: For seizure control if present.
  • Avoidance of vasoconstrictors: Sympathomimetics should generally be avoided.

• Non-pharmacological:

  • Surgical Revascularization:
    • Direct bypass surgery: Involves anastomosing a superficial temporal artery (STA) to a middle cerebral artery (MCA) branch (STA-MCA bypass). This provides immediate, increased blood flow to the ischemic brain region.
    • Indirect revascularization (encephaloduroarteriosynangiosis [EDAS], encephalomyosynangiosis [EMS], encephalogaleosynangiosis [EGAS]): Involves placing a vascularized tissue (e.g., temporalis muscle, dura, galea) onto the brain surface, encouraging new collateral vessel formation over weeks to months. Often preferred in children due to smaller vessel size and technical challenges of direct bypass.
    • Combined direct and indirect bypass: May be performed in adults.
    • Goal: To improve cerebral blood flow, prevent further ischemic strokes, reduce TIA frequency, and decrease the risk of hemorrhagic stroke by normalizing hemodynamic stress on fragile collateral vessels.
    • Indication: Symptomatic MMD (ischemic or hemorrhagic), or often in asymptomatic cases with evidence of reduced cerebrovascular reserve.
  • Lifestyle modifications:
    • Hydration: Maintain good hydration to avoid hemoconcentration and reduced CBF.
    • Avoid hyperventilation: Advise patients to avoid activities that induce hyperventilation (e.g., excessive crying, blowing up balloons, strong emotion without breath control).
    • Management of associated conditions: Strict control of diabetes, hypertension, and effective management of any underlying conditions contributing to Moya Moya syndrome (e.g., managing sickle cell disease, thyroid disorders).
    • Smoking cessation: Reduces general stroke risk.
    • Physical activity: Regular, moderate exercise, avoiding strenuous exertion that might trigger symptoms.
    • Cognitive rehabilitation: For patients with cognitive deficits.

• Monitoring:

  • Regular neurological examinations: To detect progression or new symptoms.
  • Repeat imaging (MRA/CTA/DSA): Typically performed post-surgery (e.g., 6 months to 1 year) to assess bypass patency and collateral formation, and periodically thereafter to monitor disease progression or development in the contralateral hemisphere.
  • TCD/Perfusion imaging (SPECT/PET): To monitor cerebral blood flow and cerebrovascular reserve, especially in the non-operated hemisphere or to assess revascularization efficacy.
  • Neuropsychological assessment: Periodically, especially in children, to monitor cognitive function.

Treatment Algorithms

• First-Line:

  1. Diagnosis confirmation: DSA is gold standard, MRA/CTA for initial screening.
  2. Symptomatic MMD (ischemic or hemorrhagic): Revascularization surgery (STA-MCA direct bypass, EDAS/EMS, or combined) as the primary treatment to prevent further events.
  3. Asymptomatic MMD:
     • Evidence of impaired cerebrovascular reserve (e.g., on acetazolamide challenge SPECT/PET/perfusion MRI): Surgical revascularization is often recommended due to high risk of future events.
     • No impaired reserve but significant angiographic stenosis: Close observation with consideration for surgery based on individual risk factors and patient preference.
  4. Antiplatelet therapy: Low-dose aspirin for all patients, unless contraindicated, particularly while awaiting surgery or if surgery is not an option.

• Second-Line:

  • Combined procedures: For challenging cases or in children where indirect bypass may be insufficient, a combination of indirect and direct approaches may be considered.
  • Repeat revascularization: If initial surgery fails or contralateral progression occurs.

• Refractory Cases:

  • Aggressive medical management: Optimization of antiplatelet therapy, blood pressure control, and management of any identified triggers or comorbidities.
  • Alternative revascularization techniques: In selected centers, other bypass options (e.g., using radial artery grafts, occipital artery) may be explored.
  • Symptomatic management: Focus on optimizing quality of life and managing complications (e.g., anti-seizure medications, pain management for headaches).

Complications

• Common:

  • Transient Ischemic Attacks (TIAs): Recurrent brief episodes of neurological dysfunction.
  • Ischemic Stroke: Leading to fixed neurological deficits, cognitive impairment.
  • Chronic Headaches: Often severe, debilitating.
  • Cognitive Decline: Especially in children with recurrent ischemia.

• Serious:

  • Intracerebral Hemorrhage (ICH): More common in adults, often severe with high morbidity and mortality. Can be spontaneous or associated with rupture of fragile Moya Moya vessels or related aneurysms.
  • Subarachnoid Hemorrhage (SAH): Less common than ICH but can occur.
  • Recurrent Strokes: Both ischemic and hemorrhagic, leading to cumulative neurological damage.
  • Vascular Dementia: Severe cognitive impairment due to widespread cerebral ischemia.
  • Seizures: As a consequence of stroke or hemorrhage.

• Long-term:

  • Permanent neurological deficits: Hemiparesis, aphasia, visual field defects, sensory loss.
  • Epilepsy: Chronic seizure disorder requiring long-term medication.
  • Psychiatric sequelae: Depression, anxiety, behavioral changes.
  • Reduced quality of life: Due to physical limitations and cognitive impairment.

Prognosis

• Factors:

  • Age of onset: Childhood-onset MMD generally has a worse prognosis for cognitive development due to the developing brain being more vulnerable to recurrent ischemia. Adult-onset MMD has a higher risk of hemorrhagic stroke.
  • Presentation type: Patients presenting with hemorrhage tend to have a worse prognosis than those presenting with ischemia.
  • Severity of stenosis and collateralization: More advanced disease (less robust collateralization despite severe stenosis) may indicate higher risk.
  • Timing and efficacy of revascularization surgery: Early and successful revascularization significantly improves outcomes and prevents progression.
  • Presence of underlying Moya Moya syndrome: Some associated conditions (e.g., NF1, sickle cell disease) can independently affect prognosis.
  • Development of contralateral disease: Even if unilateral initially, progression to bilateral disease affects long-term prognosis.

• Survival:

  • Untreated MMD has a significant risk of recurrent stroke and neurological deficit. The annual risk of stroke in untreated MMD varies: for ischemic events, 10-20% per year; for hemorrhagic events, 3-7% per year.
  • Surgical revascularization significantly reduces the risk of stroke, with an estimated stroke reduction of 80-90%.
  • Life expectancy can be reduced, particularly with severe, recurrent hemorrhagic events or extensive ischemic damage. However, with successful revascularization, many patients can lead relatively normal lives.

• Quality of Life:

  • Improved with surgery: Surgical revascularization demonstrably improves neurologic outcome and quality of life by preventing future strokes and improving cerebral perfusion.
  • Children: May achieve better intellectual function and academic performance post-surgery compared to those managed medically.
  • Adults: Can experience significant reduction in stroke risk, cognitive improvement, and resolution of headaches.
  • Challenges: Some patients may still experience residual neurological deficits, cognitive issues, or chronic headaches despite successful surgery.

Prevention

• Primary:

  • Genetic Counseling: For families with a history of MMD, particularly in the familial form.
  • Screening for associated conditions: Early identification and management of conditions known to cause Moya Moya syndrome (e.g., close monitoring of cranial vessels in NF1 patients).
  • Avoidance of cranial radiation in high-risk individuals: If possible, or careful risk-benefit analysis.

• Secondary:

  • Early diagnosis: Recognizing symptoms (especially recurrent TIAs in children) and promptly initiating diagnostic work-up.
  • Surgical revascularization: This is the cornerstone of secondary prevention, aiming to prevent future ischemic and hemorrhagic strokes in diagnosed patients.
  • Antiplatelet therapy: Long-term low-dose aspirin in symptomatic patients to reduce ischemic events.

• Tertiary:

  • Ongoing medical management: Control of blood pressure, prevention of dehydration, management of comorbidities.
  • Neurological and developmental follow-up: Regular assessments to detect and manage new deficits or complications.
  • Rehabilitation: Physical, occupational, and speech therapy for patients with residual neurological deficits.
  • Neuropsychological support: For cognitive and psychological well-being.

Special Populations

• Pediatric:

  • Presentation: More commonly present with ischemic events and TIAs, often triggered by hyperventilation. Cognitive decline and developmental delay are significant concerns.
  • Treatment: Indirect revascularization (EDAS, EMS) is often preferred due to smaller vessel size and increased potential for angiogenesis. Direct bypass (STA-MCA) can be more challenging but may be used.
  • Prognosis: Early surgery is crucial to preserve cognitive function and prevent irreversible brain damage.

• Geriatric:

  • Presentation: More likely to present with hemorrhagic stroke. Ischemic strokes and cognitive issues also occur.
  • Treatment: Surgical intervention is considered, but individual risk assessment for general anesthesia and surgical morbidity is critical. Medical management might be preferred in frail patients. Indirect bypass may also be considered in older patients.
  • Comorbidities: Higher prevalence of hypertension, diabetes, and other cardiovascular risk factors requiring careful management.

• Pregnancy:

  • Increased risk: Pregnancy is associated with an increased risk of both ischemic and hemorrhagic strokes in MMD patients, possibly due to hemodynamic changes (increased blood volume, hypercoagulability, varying blood pressure).
  • Management: Close monitoring of blood pressure, ensuring adequate hydration. Elective revascularization ideally before pregnancy. Delivery options need to be considered: vaginal delivery may be possible with adequate pain management and avoidance of prolonged Valsalva, but cesarean section may be preferred if there's high risk of hemorrhage. Careful anesthetic management.

• Comorbidities:

  • Sickle Cell Disease: MMD is a serious complication, often leading to severe ischemic strokes. Transfusions to reduce hemoglobin S, and aggressive revascularization are key.
  • Down Syndrome: Increased risk of MMD. Higher surgical risks, especially related to anesthesia and atlantoaxial instability, must be considered.
  • Neurofibromatosis Type 1 (NF1): MMD is a recognized vasculopathy. Management includes addressing other NF1-related complications.
  • Graves' Disease: Control of thyroid function is essential. MMD treatment (surgery) may proceed once thyroid function is optimized.
  • Post-Radiation MMD: Often unilateral initially and progresses faster. Revascularization is usually indicated.

Clinical Pearls

• Diagnostic:

  • "Puff of smoke" on angiography is pathognomonic, but often MRA can provide sufficient diagnostic certainty. DSA remains the gold standard for detailed surgical planning.
  • Always consider Moya Moya in young patients with recurrent TIAs or unexplained stroke, especially if precipitated by hyperventilation.
  • Unilateral MMD is often a sign of Moya Moya syndrome and warrants a thorough search for an underlying cause. Progression to bilateral disease is common.
  • Perfusion imaging (SPECT, PET, or MR perfusion with acetazolamide challenge) is critical to identify patients at high risk for future stroke, even if asymptomatic.

• Treatment:

  • Surgical revascularization is the only treatment that alters the natural history of MMD. Medical management alone is insufficient to prevent progression.
  • Early intervention is key, especially in children, to preserve cognitive function.
  • Indirect bypass is often preferred in children, while direct bypass (STA-MCA) is commonly performed in adults, sometimes in combination with indirect methods.
  • Bilateral disease usually requires bilateral surgery, typically staged with several months between procedures.
  • Monitor for stroke on the contralateral side after unilateral surgery, as disease progression can occur.

• Pitfalls:

  • Misdiagnosing MMD as typical atherosclerotic disease due to unfamiliarity, leading to inappropriate treatments (e.g., aggressive anti-atherosclerotic medications without revascularization).
  • Overlooking underlying conditions in Moya Moya syndrome, which may require specific management.
  • Underestimating the risk of hemorrhage in adults and managing them solely for ischemia.
  • Delaying surgical referral, leading to irreversible neurological deficits, especially in children.
  • Inadequate postoperative monitoring for bypass patency and continued disease progression.

Recent Updates

• Guidelines: The 2017 AHA/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke reinforce the role of surgical revascularization for symptomatic MMD. Japanese Guidelines for Moyamoya Disease (2021) provide comprehensive recommendations on diagnosis and treatment.
• Evidence:
  • Growing evidence supports the utility of genomic sequencing for RNF213 variants, particularly in East Asian populations, and in familial cases, aiding in diagnosis and understanding pathophysiology.
  • Advances in perfusion imaging techniques (e.g., quantitative cerebral blood flow measurements) allow for more precise identification of hemodynamic compromise and improved patient selection for surgery.
  • Long-term follow-up studies continue to demonstrate the superior outcomes of surgical revascularization compared to conservative management in preventing stroke and improving quality of life.
  • Research into novel indirect revascularization techniques and optimal surgical strategies for different age groups and disease stages.
• Controversies:
  • Role of surgery in asymptomatic MMD: While impaired cerebrovascular reserve is generally an indication, the precise threshold for surgery in certain asymptomatic populations (e.g., those without strong indicators of hypoperfusion) remains debated.
  • Optimal timing of bilateral procedures: Whether concurrent or staged bilateral revascularization is better, particularly in children.
  • Medical management strategies: The optimal antiplatelet regimen and the role of other pharmacological agents for symptom control given that surgery is the only disease-modifying treatment.
  • Pathogenesis: While RNF213 is a recognized major genetic risk factor, the full understanding of MMD pathogenesis, especially in non-East Asian populations and for sporadic cases, is still evolving.

Key References

• Guidelines:

  • Japanese Stroke Society. Guidelines for Moyamoya Disease (2021 edition). (Specific to major region with high prevalence, highly influential recommendations).
  • American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update. (Includes recommendations on MMD treatment within stroke guidelines).

• Studies:

  • SURPASS Study (Stenosis/Occlusion bypass versus Aggressive Medical Management Randomized Trial in Patients with Moyamoya Disease): Current ongoing trials that aim to provide higher-level evidence for surgical vs. medical management in adult MMD.
  • Representative papers on RNF213 gene mutations and their association with MMD (e.g., by Kamada, Inoue, Liu et al.).
  • Major surgical outcome series and meta-analyses comparing direct, indirect, and combined revascularization techniques for efficacy and safety (e.g., Miyamoto, Kuroda, Scott et al. publications).

• Reviews:

  • Specific review articles in high-impact neurological and neurosurgical journals (e.g., Stroke, Neurosurgery, Journal of Neurosurgery, Lancet Neurology) dedicated to MMD, summarizing current understanding of pathophysiology, diagnosis, and treatment.
  • UpToDate and DynaMed: Comprehensive medical resources that frequently update their content on MMD.